Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Fructose on Metabolism and MR Biomarkers in NAFLD
NCT01930123Phase 2Terminated
- Start
- Oct 2013
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Fructose Diphosphate Sodium Injection in non-alcoholic fatty liver disease (NAFLD). Started Oct 2013; status: terminated.
02
Drugs
Fructose Diphosphate Sodium Injection
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT01930123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01930123.